Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Fatostatin

Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice[1][2].

Product Specifications

CAS Number

[125256-00-0]

Product Name Alternative

125B11

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Fatty Acid Synthase (FASN)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Fatostatin-A.html

Purity

99.85

Solubility

DMSO : ≥ 27 mg/mL

Smiles

CCCC1=NC=CC(C2=NC(C3=CC=C(C)C=C3)=CS2)=C1

Molecular Formula

C18H18N2S

Molecular Weight

294.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Li X et al. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014 Apr;13 (4) :855-66.|[2]Shao W et al. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res. 2016 Aug;57 (8) :1564-73.|[3]Inoue K et al. Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation. Biochim Biophys Acta. 2015 Nov;1852 (11) :2432-41.|[4]Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003 Feb 28;278 (9) :7320-4.|[5]Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009 Aug 28;16 (8) :882-92.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Adv Sci (Weinh) . 2025 Apr 24:e2407671.|Autophagy. 2021 Jul;17 (7) :1592-1613.|Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jun 6:159642.|Biol Pharm Bull. 2022 Apr 1;45 (4) :438-445.|Br J Nutr. 2024 Feb 28;131 (4) :553-566.|Cancer Cell. 2024 Sep 26:S1535-6108 (24) 00350-7.|Cancer Lett. 2024 Jun 18:217068.|Cancers (Basel) . 2023 Jun 3;15 (11) :3043.|Cell Biosci. 2023 Oct 3;13 (1) :186.|Cell Death Differ. 2021 Jun;28 (6) :2001-2018.|Cell Death Dis. 2021 May 26;12 (6) :544.|Cell Death Dis. 2024 Jun 12;15 (6) :411.|Cell Death Dis. 2025 May 16;16 (1) :391.|Cell Death Discov. 2022 Oct 28;8 (1) :431.|Cell Metab. 2021 Aug 3;33 (8) :1655-1670.e8.|Cell Mol Biol Lett. 2024 Aug 21;29 (1) :112.|Cell Mol Immunol. 2025 Oct 29.|Cell Mol Life Sci. 2024 Jul 6;81 (1) :289.|Cell Mol Life Sci. 2025 Jul 3;82 (1) :270.|Cell Rep. 2022 Nov 29;41 (9) :111738.|Cell Rep. 2025 Feb 19;44 (3) :115339.|Emerg Microbes Infect. 2025 Dec;14 (1) :2470371.|Eur J Pharmacol. 2025 Sep 15:1003:177890.|Exp Eye Res. 2025 Jan 10:110239.|Int Immunopharmacol. 2024 Jul 18:139:112669.|iScience. 2024 Jun 29;27 (8) :110424.|J Cell Mol Med. 2025 Jul;29 (14) :e70710.|J Clin Invest. 2025 Jul 8:e193134.|J Ethnopharmacol. 2024 Jan 30;319 (Pt 1) :117162.|J Ethnopharmacol. 2026 Feb 28:357:120890.|J Exp Clin Cancer Res. 2019 May 29;38 (1) :228. |J Pathol. 2020 Dec;252 (4) :358-370.|JCI Insight. 2024 Jun 18:e180132.|Mol Carcinog. 2023 Jul;62 (7) :963-974.|Mol Med. 2024 Feb 21;30 (1) :28.|Mol Oncol. 2025 Jun;19 (6) :1668-1686.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Feb 25;16 (1) :1774.|NPJ Precis Oncol. 2024 Mar 1;8 (1) :58.|Oncol Lett. 2020 Sep;20 (3) :2855-2869.|Oncol Rep. 2018 Apr;39 (4) :1919-1929.|Res Sq. 2024 Nov 18.|Research Square Preprint. 2022 May.|Tissue Cell. 2025 Sep 9:98:103134.|University of Tubingen. 2025.|Free Radic Biol Med. 2025 Aug 19:240:170-182.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

MORN4 Over-expression Lysate Product
GWB-8F3DD7 0.1 mg

MORN4 Over-expression Lysate Product

Ask
View Details
CCKBR Antibody, FITC conjugated
MBS7105967-01 0.05 mg

CCKBR Antibody, FITC conjugated

Ask
View Details
CCKBR Antibody, FITC conjugated
MBS7105967-02 0.1 mg

CCKBR Antibody, FITC conjugated

Ask
View Details
CCKBR Antibody, FITC conjugated
MBS7105967-03 5x 0.1 mg

CCKBR Antibody, FITC conjugated

Ask
View Details
CMH1 (MYH7) Human shRNA Lentiviral Particle (Locus ID 4625)
TL311311V 500 µL Each

CMH1 (MYH7) Human shRNA Lentiviral Particle (Locus ID 4625)

Ask
View Details
Vmn1r217 (NM_134239) Mouse Tagged ORF Clone
MG225126 10 µg

Vmn1r217 (NM_134239) Mouse Tagged ORF Clone

Ask
View Details